Strictly as a policy initiative, President Trump’s Rx pricing blueprint has yet to produce many formal results. Much of it would need congressional action, and the initiatives that can be accomplished administratively are in the proposal or even just conceptual stages. But that doesn’t mean that the blueprint isn’t already having an impact.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?